ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Researchers Uncover Tumors Sensitive to Chemotherapy

January 25, 2013

Natcher Subcommittee Open Door To justification for Increasing Cancer Program 1982 Appropriation

April 3, 1981

Next Bypass Budget: Slim, Trim, Modest

September 15, 1995

In Brief: Bleyer To Chair Childrens Cancer Study Group; Fisher To Advise; Penn. Awards Herberman

May 3, 1991

NIH Will Target Genomics, Translational Research, And Training, Collins Tells Congress

April 30, 2010